3 hours ago
1
jarun011/iStock via Getty Images
- Shares of Quanterix Corp. are up ~4% in Wednesday morning trading after CMS' recently released preliminary Clinical Lab Fee Schedule listed the company's LucentAD Alzheimer blood biomarker test priced at a maximum reimbursement of $897.
- The test is used along
English (US) ·